Concepedia

Author

Heidi Giordano

Clovis Oncology (United States)

Also Known As

Giordano, H, H Giordano, H. Giordano, Heidi Giordano

88

Publications

5.6K

Citations

22

H-Index

39

Concepts

All Affiliations

Clovis Oncology (United States)University College LondonThe University of Texas MD Anderson Cancer CenterUniversity of GlasgowLondon Cancer
HG

About

Heidi Giordano is an author at Clovis Oncology (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

17

3.2K

2

Health Sciences

4

4

102

3

Biochemistry

2

2

36

4

Natural Sciences

1

1

18

5

Molecular Medicine

1

1

34

Heidi Giordano

×

31

Publications

5.5K

Citations

22

H-Index

YearCitations

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso,

The Lancet

2017

1.7K

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza,

The Lancet Oncology

2016

1.2K

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza,

Cancer Discovery

2018

403

Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin,

Cancer Discovery

2017

396

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Amit M. Oza, Anna V. Tinker, Ana Oaknin,

Gynecologic Oncology

2017

272

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle,

Journal of Clinical Oncology

2011

247

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris,

Clinical Cancer Research

2017

236

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza,

Nature Communications

2021

193

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation

Rachna T. Shroff, Andrew Hendifar, Robert R. McWilliams,

JCO Precision Oncology

2018

173

Inhibition of Herpes Simplex Virus Replication by a 2-Amino Thiazole via Interactions with the Helicase Component of the UL5-UL8-UL52 Complex

F. Spector, Li Liang, Heidi Giordano,

Journal of Virology

1998

119

Page 1